 |
|
|
| Date: | Saturday, 14 June 2003 |
| Time: | 08:30-09:45 |
| Room: | Room A (Halle Tony Garnier) |
| 08:30-08:45 |
0416 |
|
|
COMPLEMENT DETERMINES THE THERAPEUTIC ACTIVITY OF RITUXIMAB IN VIVO
M. Introna, N. Di Gaetano, E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, J. Golay (Milano, Italy)
| 08:45-09:00 |
0417 |
|
|
MANTLE CELL LYMPHOMA (MCL): INCREASED CLINICAL AND MOLECULAR RESPONSE RATES BY THE ADDITION OF ARA-C AND RITUXIMAB TO CHOP BEAM AND AUTOLOGOUS STEM CELL TRANSPLANTATION
C.H. Geisler, N.S. Andersen, L.B. Pedersen, E. Elonen, A. Johnson, A. Kolstad (Copenhagen, Denmark)
| 09:00-09:15 |
0418 |
|
|
EFFICACY AND SAFETY OF RITUXIMAB IN B-CELL POST TRANSPLANTATION LYMPHOPROLIFERATIVE DISORDERS (B-PTLD): FINAL RESULTS OF A MULTICENTER, OPEN LABEL, PHASE II TRIAL (M39037 TRIAL)
S. Choquet, R. Herbrecht, G. Socie, A.M. Stoppa, P. Vandenberghe, A. Moreau, S. Fafi, K. Imadalou, W. Feremens, A. Fischer, F. Morschauser, G. Salles, E. Vilmer, J.L. Garnier, V. Leblond, N. Milpied (Le Chesnay, France)
| 09:15-09:30 |
0419 |
|
|
REPORT OF A PHASE II STUDY OF PROTEASOME INHIBITOR BORTEZOMIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT AND AGGRESSIVE B-CELL LYMPHOMAS
A. Goy, K. East, O. Mesina, F. Cabanillas, L. Fayad, F.B. Hagemeister, P. McLaughlin, B. Pro, J. Romaguera, A. Younes, M. Wang, R. Ford, F. Gilles, P. Scheinkein, E. Trehu, M.A. Rodriguez (Houston, United States of America)
| 09:30-09:45 |
0420 |
|
|
A PROSPECTIVE STUDY ON ANTIBODY RESPONSE TO REPEATED VACCINATIONS WITH PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE IN SPLENECTOMIZED INDIVIDUALS WITH SPECIAL REFERENCE TO HODGKIN'S LYMPHOMA
O. Landgren, M. Björkholm, H.B. Konradsen, M. Söderqvist, B. Nilsson, A. Gustavsson, U.A. Axdorph, M. Kalin, G. Grimfors (Stockholm, Sweden)
|